PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$51.11 USD
-1.14 (-2.18%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $51.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, PTC Therapeutics, Inc. has a market cap of $4.14B, which represents its share price of $52.25 multiplied by its outstanding shares number of 79.26M. As a mid-cap company, PTCT's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PTCT 51.11 -1.14(-2.18%)
Will PTCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTCT
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Other News for PTCT
SA analyst upgrades/downgrades: AMD, TSLA, SHEL, PTCT
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
PTC Therapeutics: Uncertainty Abounds Ahead Of Q2 Earnings - I'm Upgrading To 'Hold'
PTCT Price Target Raised to $86 by Truist Securities | PTCT Stock News
PTC Therapeutics (PTCT) Sees Raised Price Target by B of A Securities | PTCT Stock News